| OVERLAND-THERAPEUTICS-INC |
OVERLAND-THERAPEUTICS-INC |
90%
|
Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| OVERLAND-THERAPEUTICS-SH-CO-LTD |
OVERLAND-THERAPEUTICS-SH-CO-LTD |
90%
|
Under the License Agreement, the Company received an upfront payment $40.0 million and non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland |
| AZN |
AstraZeneca PLC |
72%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLO graph: y suffer if government and other thir… |
| CLLS |
Cellectis S.A. |
72%
|
is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-y… |
| CLLS |
Cellectis S.A. |
72%
|
Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research pr… |
| CRBU |
Caribou Biosciences, Inc. |
72%
|
Reciprocal relationship from CRBU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the… |
| FATE |
Fate Therapeutics, Inc. |
72%
|
Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely… |
| GDTC |
CytoMed Therapeutics Limited |
72%
|
Reciprocal relationship from GDTC graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the… |
| INAB |
IN8bio, Inc. |
72%
|
Reciprocal relationship from INAB graph: nt to the UABRF license agreement, see the section titled “Business—Intellectual Property.” Sales and Marketing Given our stage of development, we have not ye… |
| JPM-PD |
JPMorgan Chase & Co. |
72%
|
Reciprocal relationship from JPM-PD graph: Reciprocal relationship from ALLO graph: to business disruptions, including those caused by earthquakes, power shortages, telecommunications failures, cyber… |
| JPM-PD |
JPMorgan Chase & Co. |
72%
|
to business disruptions, including those caused by earthquakes, power shortages, telecommunications failures, cybersecurity attacks, water shortages, floods, hurricanes, tsunamis, typhoons, fires, ex… |
| LEGN |
Legend Biotech Corporation |
72%
|
Reciprocal relationship from LEGN graph: ct and product candidates have a limited window of stability following apheresis from a patient, we must establish and employ complex logistical operations, i… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect do… |
| TCRX |
TScan Therapeutics, Inc. |
72%
|
Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel… |
| ARBOR-BIOTECHNOLOGY-INC |
ARBOR-BIOTECHNOLOGY-INC |
62%
|
that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ry approval of an MRD assay for use as an in vitro diagnostic with cema-cel. On February 19, 2025, we entered into an Amended and Restated Strategic Collaboration Agreement with Foresight Diagnostics… |
| FACTOR-BIOSCIENCE-INC |
FACTOR-BIOSCIENCE-INC |
62%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| FBIO |
Fortress Biotech, Inc. |
62%
|
Reciprocal relationship from FBIO graph: Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect do… |
| FORESIGHT-DIAGNOSTICS-INC |
FORESIGHT-DIAGNOSTICS-INC |
62%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| LIFE |
LIFE |
62%
|
Reciprocal relationship from LIFE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LIFE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from LIFE g… |
| LIFE-TECHNOLOGIES-CORPORATION |
LIFE-TECHNOLOGIES-CORPORATION |
62%
|
is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-y… |
| ROCHE-MOLECULAR-SYSTEMS-INC |
ROCHE-MOLECULAR-SYSTEMS-INC |
62%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| ROCHE-SEQUENCING-SOLUTIONS-INC |
ROCHE-SEQUENCING-SOLUTIONS-INC |
62%
|
y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies … |
| SI |
Shoulder Innovations, Inc. |
62%
|
Reciprocal relationship from SI graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from SI graph: Reciprocal relationship from ALLO graph: to business disruptions, including thos… |
| SILVERGATE-CAPITAL-CORP |
SILVERGATE-CAPITAL-CORP |
62%
|
to business disruptions, including those caused by earthquakes, power shortages, telecommunications failures, cybersecurity attacks, water shortages, floods, hurricanes, tsunamis, typhoons, fires, ex… |
